{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Immunoglobulin&page=2", "query": { "intervention": "Intravenous Immunoglobulin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 2129, "total_pages": 213, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Immunoglobulin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Immunoglobulin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T03:31:28.806Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01841619", "title": "IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "IVIg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2013-03", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2015-08-10", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 2, "location_summary": "Irvine, California", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01841619" }, { "nct_id": "NCT03449030", "title": "A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies" ], "interventions": [ { "name": "TAK-164", "type": "DRUG" }, { "name": "89Zr-TAK-164", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2018-04-23", "completion_date": "2020-02-27", "has_results": true, "last_update_posted_date": "2021-03-22", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 4, "location_summary": "Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449030" }, { "nct_id": "NCT04093531", "title": "Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Sjögren Syndrome" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2020-01-15", "completion_date": "2022-05-11", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04093531" }, { "nct_id": "NCT05327530", "title": "A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Sacituzumab Govitecan (SG)", "type": "DRUG" }, { "name": "M6223", "type": "DRUG" }, { "name": "NKTR-255", "type": "DRUG" }, { "name": "JB100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2022-08-17", "completion_date": "2027-01-22", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 8, "location_summary": "Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more", "locations": [ { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05327530" }, { "nct_id": "NCT02807636", "title": "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1213, "start_date": "2016-06-30", "completion_date": "2024-02-12", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 18, "location_summary": "Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02807636" }, { "nct_id": "NCT06101134", "title": "A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "relatlimab+nivolumab", "type": "DRUG" }, { "name": "relatlimab+nivolumab+rHuPH20", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "nivolumab+rHuPH20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-11-06", "completion_date": "2026-12-21", "has_results": true, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 9, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • San Francisco, California + 6 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Edgewood", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06101134" }, { "nct_id": "NCT00298272", "title": "Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "IDEC-C2B8 (rituximab)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Folate", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2006-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298272" }, { "nct_id": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Non-small Cell Lung Carcinoma" ], "interventions": [ { "name": "Trastuzumab deruxtecan (DS-8201a)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2020-02-10", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 10, "location_summary": "San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04042701" }, { "nct_id": "NCT00660881", "title": "Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Epratuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2008-05", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-07-12", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00660881" }, { "nct_id": "NCT02176031", "title": "Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-01", "completion_date": "2019-02", "has_results": true, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-10-02T03:31:28.806Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02176031" } ] }